603259 Share Price Performance
CN¥0
-70.72 (-100.00%)
Price CN¥0
Fair ValueCN¥145.96
Share Pricen/a
Narrative Update • Jun 29
WuXi AppTec Co., Ltd. Stock Price
- 4 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
603259 Community Narratives
AN
Fair Value
·Fair Value CN¥145.96 15.0% undervalued intrinsic discount
Upcoming Meetings and Capital Moves Will Drive Long-Term Opportunities
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
DD
Fair Value
·Fair Value CN¥124.31 0.2% undervalued intrinsic discount
Why is WuXi AppTec a company of the future?
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value CN¥169.13 26.6% undervalued intrinsic discount
Global Aging And Advanced Therapies Will Expand Outsourcing
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Why is WuXi AppTec a company of the future?
WuXi AppTec (603259.SH / 2359.HK) — this is not just a pharmaceutical company; it is the "infrastructure foundation" of the global bio-industry. It operates under the CRDMO (Contract Research, Development, and Manufacturing Organization) model, providing services from molecule discovery to mass production of drugs.Read more
Upcoming Meetings and Capital Moves Will Drive Long-Term Opportunities
WuXi AppTec helps drug companies research and make medicines, and a growing pipeline of higher-value projects plus rising demand for outsourcing could keep its business expanding. But its dependence on overseas customers and China-based capacity means politics, regulation, and tougher local competition could quickly dent growth.Read more
AN
CN¥145.96
15.0% undervalued intrinsic discount
Fair Value
Revenue
17.36% p.a.
Profit Margin
32.41%
Future PE
17.97x
Price in 2029
CN¥181.23
Rising Geopolitical And Regulatory Pressures Will Crash Profits
WuXi AppTec faces a growing squeeze as politics and new rules could make it harder to serve major drug makers outside China, just as the industry shifts toward local supply chains. The key question is whether its fast-growing service lines and efficiency push can keep profits rising despite tougher access, more competition, and big expansion plans.Read more
AN
CN¥124.4
0.2% undervalued intrinsic discount
Fair Value
Revenue
16.06% p.a.
Profit Margin
30.74%
Future PE
16.68x
Price in 2029
CN¥154.26
Global Aging And Advanced Therapies Will Expand Outsourcing
WuXi AppTec helps drugmakers research and manufacture medicines, and its rapid expansion into new facilities and advanced therapies could let it win more long-term work from big pharma customers. But rising political friction between China and the West, along with tougher rules and pricing pressure, could threaten those relationships and squeeze profits.Read more
AN
CN¥169.13
26.6% undervalued intrinsic discount
Fair Value
Revenue
24.94% p.a.
Profit Margin
33.83%
Future PE
16.44x
Price in 2029
CN¥208.78
Trending Discussion
Recently Updated Narratives
DD
Why is WuXi AppTec a company of the future?
Fair Value: CN¥124.31 0.2% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
603259: APAC Conviction List Inclusion Will Support Upside From Ongoing Share Buybacks
Fair Value: CN¥145.96 15.0% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
603259: Conviction List Addition Will Support Confidence In 2026 Buyback Plan
Fair Value: CN¥124.4 0.2% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
WuXi AppTec Co., Ltd. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
Aug 04, 2026
- 6.32
- 50.70%
- 40.69%
- 9.4%
About 603259
- Founded
- 2000
- Employees
- 33834
- CEO
- WebsiteView website
WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People’s Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People’s Republic of China.
